Assessment of Effectiveness of Belatacept Patient Alert Card in Patients Following Renal Transplantation in a Sample of EU Countries

Bristol-Myers Squibb (BMS)

Status

Completed

Conditions

Renal Transplant

Study type

Observational

Funder types

Industry

Identifiers

NCT02581644

IM103-367

Details and patient eligibility

About

The purpose of the study is to determine a) if the implementation of belatacept patient alert card (PAC) resulted in effective understanding of key safety messages and b) if the degree of understanding of key safety messages is associated with improved clinical and safety outcomes.

Full description

3 sub studies: 2 Cross-Sectional and 1 retrospective chart review

Enrollment

63 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient survey (cohort 1):
Patients has taken belatacept within the previous 3 months for renal transplantation
Patient is over 18 years of age
HCP survey (cohort 2):
Physician or nurses working in nephrology centers, with at least 1 patient taking belatacept in the previous 6 months for renal transplantation (by prescribing, administering or by follow up)
Retrospective chart review study (cohort 3):
Patient survey questionnaire received, Informed Consent Form (ICF) signed (if required)

Exclusion criteria

Patient survey:
Patient has participated in a clinical trial for their renal condition in the previous 12 months
Currently an employee of BMS
HCP survey:
Physicians or nurse who have recruited patients for the Patient survey
Currently an employee of BMS